Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

Summary

CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke, that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due to the build up of plaque, will be randomly assigned to receive either low-dose rivaroxaban + aspirin or aspirin alone.

Timeline

Start

2020-02-03

Primary completion

2023-09-18

Completion

2023-09-18

Outcome

Missed primary endpoint

paper with a hazard ratio of 0.78 ([95% CI, 0.32-1.93]; P=0.59) favoring the intervention. PMID 39781748 ↗

paper A numerical trend toward efficacy for the composite primary end point of symptomatic ischemic stroke and covert infarcts was observed. PMID 39781748 ↗

Publications

• Perera KS, Sharma MA, Eikelboom JW, Ng KKH, Field TS, Buck BH, Hill MD, Stotts G, Casaubon LK, Mandzia J, Katsanos AH, Yip S, Shoamanesh A, Young GB, Appireddy R, Nayar S, Swartz R, Taylor A, Carrier A, Srivastava A, Deshmukh AS, Zhao R, Hart RG; CATIS-ICAD Investigators. Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease. Stroke. 2025 Feb;56(2):380-389. doi: 10.1161/STROKEAHA.124.047715. Epub 2025 Jan 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	2.5 mg	Oral
Background	Acetylsalicyclic acid	Unknown	81 mg	—

Indications